Maine Medical Partners Neurology

Scarborough, Maine 04074

0 studies enrolling now · 11 studies all time

What they study most

Alzheimer's Disease, Brain and Central Nervous System Tumors, Focal Epilepsy, Gliosarcoma, Grade 2 Glioma, MGMT-Unmethylated Glioblastoma, Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy, Parkinson Disease Psychosis, Partial Epilepsy, Recurrent Glioma, Residual Glioma

Studies at this site

• Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma — Completed
• Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma — Running, not enrolling
• Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) — Running, not enrolling
• Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis — Completed
• A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy — Running, not enrolling
• Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures — Completed
• ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures — Withdrawn before enrolling
• Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy — NO_LONGER_AVAILABLE
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed